Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials

Tinahones Francisco J.; Gallwitz Baptist; Nordaby Matias; Goetz Sophia; Maldonado-Lutomirsky Mario; Woerle Hans J.; Broedl Uli C.

首页> 外文期刊>Diabetes, obesity & metabolism >Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials

【24h】

Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials

机译：Linagliptin作为2型糖尿病患者的Empagliflozin和二甲双胍的加载项：两个24周随机化，双盲，双伪，并行组试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: To evaluate the efficacy and safety of linagliptin vs placebo as add-on to empagliflozin and metformin in patients with type 2 diabetes.

机译：目的：评价Linagliptin VS安慰剂作为2型糖尿病患者的Empagliflozin和二甲双胍的加入效果和安全性。

著录项

来源
《Diabetes, obesity & metabolism》 |2017年第2期|共9页
作者
Tinahones Francisco J.; Gallwitz Baptist; Nordaby Matias; Goetz Sophia; Maldonado-Lutomirsky Mario; Woerle Hans J.; Broedl Uli C.;
展开▼
作者单位

Univ Malaga Dept Diabet Endocrinol &

Nutr Inst Invest Biomed Malaga IBIMA Hosp Univ Virgen de la;

Eberhard Karls Univ Tubingen Dept Med Endocrinol Diabet Angiol Nephrol &

Clin Tubingen Germany;

Boehringer Ingelheim Pharma GmbH &

Co KG Biberach Germany;

Boehringer Ingelheim Pharma GmbH &

Co KG Biberach Germany;

Boehringer Ingelheim Pharma GmbH &

Co KG Ingelheim Germany;

Boehringer Ingelheim Pharma GmbH &

Co KG Ingelheim Germany;

Boehringer Ingelheim Pharma GmbH &

Co KG Ingelheim Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
DPP-IV inhibitor; glycaemic control; metformin; SGLT2 inhibitor;

机译：DPP-IV抑制剂;血糖控制;二甲双胍;SGLT2抑制剂;

相似文献

外文文献
中文文献
专利

1. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials [J] . Tinahones Francisco J., Gallwitz Baptist, Nordaby Matias, Diabetes, obesity & metabolism . 2017,第2期

机译：Linagliptin作为2型糖尿病患者的Empagliflozin和二甲双胍的加载项：两个24周随机化，双盲，双伪，并行组试验
2. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial [J] . H?ring,H.-U., Merker,L., Seewaldt-Becker,E., Diabetes care . 2013,第11期

机译：Empagliflozin作为2型糖尿病患者二甲双胍和磺脲类药物的补充：一项为期24周，随机，双盲，安慰剂对照的研究
3. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension [J] . Jin S-M, Park C-Y, Cho Y. M., Diabetes, obesity & metabolism . 2015,第6期

机译：洛贝格列酮和吡格列酮作为2型糖尿病患者二甲双胍的附加药物：一项为期24周，多中心，随机，双盲，平行组，主动控制的III期临床试验，延长了28周
4. Empagliflozin and linagliptin ameliorate podocyte injury and enhance autophagy in a model of type 2 diabetic nephropathy [C] . Anton Korbut, Vadim. Klimontov, Iuliia Taskaeva, . 2018

机译：Empagliflozin和linagliptin改善2型糖尿病肾病模型中的足细胞损伤并增强自噬
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized double-blind study [O] . M Bajaj, R Gilman, S Patel, -1

机译：利格列汀改善了二甲双胍和吡格列酮联用不能充分控制的2型糖尿病患者的血糖控制而无体重增加或低血糖：一项为期24周的随机双盲研究
7. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial [O] . Eirik Søfteland, Juris J. Meier, Bente Vangen, 2016

机译：Empagliflozin作为2型糖尿病患者的加载疗法，用Linagliptin和二甲双胍对型糖尿病患者：24周随机化，双盲，并联群试验

Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials

摘要

著录项

相似文献

相关主题

期刊订阅